| Combination osimertinib and gefitinib in C797S and T790M EGFR-mutated non–small cell lung cancer S Arulananda, H Do, A Musafer, P Mitchell, A Dobrovic, T John Journal of Thoracic Oncology 12 (11), 1728-1732, 2017 | 171 | 2017 |
| BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ... Cell death & disease 10 (5), 342, 2019 | 163 | 2019 |
| Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a … EL Mitchell, PKH Lau, C Khoo, D Liew, J Leung, B Liu, A Rischin, ... European Journal of Cancer 105, 88-102, 2018 | 62 | 2018 |
| Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma S Arulananda, B Thapa, M Walkiewicz, GV Zapparoli, DS Williams, ... Journal of Thoracic Oncology 13 (10), 1588-1594, 2018 | 46 | 2018 |
| A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma S Arulananda, M O’Brien, M Evangelista, LJ Jenkins, AR Poh, ... Cell death discovery 7 (1), 122, 2021 | 29 | 2021 |
| A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia JD Lickliter, HK Gan, M Voskoboynik, S Arulananda, B Gao, A Nagrial, ... Drug design, development and therapy, 1177-1189, 2020 | 27 | 2020 |
| BCL-XL is an actionable target for treatment of malignant pleural mesothelioma S Arulananda, M O’Brien, M Evangelista, TJ Harris, NS Steinohrt, ... Cell death discovery 6 (1), 114, 2020 | 16 | 2020 |
| Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report G Lie, A Weickhardt, L Kearney, Q Lam, T John, D Liew, S Arulananda Translational lung cancer research 9 (2), 360, 2020 | 14 | 2020 |
| The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma S Arulananda, EF Lee, WD Fairlie, T John Expert review of anticancer therapy 21 (4), 413-424, 2021 | 12 | 2021 |
| Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease S Arulananda, H Do, G Rivalland, Z Loh, A Musafer, E Lau, P Mitchell, ... Journal of thoracic disease 11 (5), 1756, 2019 | 10 | 2019 |
| Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso N McNamee, C Harvey, L Gray, T Khoo, L Lingam, B Zhang, U Nindra, ... Journal of Thoracic Oncology 19 (4), 636-642, 2024 | 8 | 2024 |
| A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases S Arulananda, S Parakh, J Palmer, M Goodwin, MC Andrews, J Cebon Cancer Reports 2 (4), e1183, 2019 | 8 | 2019 |
| BRAF Mutations—A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC? S Arulananda, P Mitchell Journal of Thoracic Oncology 13 (8), 1055-1057, 2018 | 8 | 2018 |
| Circulating tumour DNA (ctDNA) as a predictor of clinical outcome in non-small cell lung cancer undergoing targeted therapies: a systematic review and meta-analysis FY Zaman, A Subramaniam, A Afroz, Z Samoon, D Gough, S Arulananda, ... Cancers 15 (9), 2425, 2023 | 7 | 2023 |
| RET‐rearranged non‐small‐cell lung cancer and therapeutic implications Z Loh, P Mitchell, T John, S Arulananda Internal medicine journal 49 (12), 1541-1545, 2019 | 7 | 2019 |
| Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion Y Zheng, M Zhou, S Arulananda, SW Um, H Li Journal of thoracic disease 12 (3), 159, 2020 | 6 | 2020 |
| Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients S Arulananda, J Lynam, M Sem Liew, M Wada, L Cher, HK Gan Internal medicine journal 48 (10), 1206-1214, 2018 | 6 | 2018 |
| Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report A Gunjur, G Chong, A Lim, E Lau, P Mitchell, T John, S Arulananda Clinical lung cancer 21 (2), e57-e60, 2020 | 5 | 2020 |
| DDR Alterations as a Surrogate Marker for TMB in SCLC—Use it or Lose it? S Arulananda, P Mitchell, T John Journal of Thoracic Oncology 14 (9), 1498-1500, 2019 | 4 | 2019 |
| Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold S Arulananda, P Mitchell Translational lung cancer research 7 (Suppl 4), S388, 2018 | 4 | 2018 |
